• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic
  • Guestorial: Demand for Nationalization of Healthcare Services in India
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea
  • Phablecare Raises ₹187 Cr In Funding
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»BioResearch - Industry»Are too many Phase III cancer clinical trials set up to fail?

Are too many Phase III cancer clinical trials set up to fail?

0
By Biotech Express on September 23, 2021 BioResearch - Industry, Biotech News - India

New research in the September 2021 issue of JNCCN — Journal of the National Comprehensive Cancer Network finds that more than 80% of therapies tested in Phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival. The researchers analyzed 362 industry-sponsored Phase III randomized trials in oncology from 2008 to 2017, and found that 87% were either false-positive or true-negative for meeting overall survival goals. More than half of the initially reported positive trials were found to be false-positive (58.4%) for overall survival, while the overwhelming majority of negative results were determined to be true-negative (with only 0.9% false-negative).

Dr. Shen continued: “Our study shows that reducing false positive errors by imposing more stringent statistical threshold in Phase III trials is not likely to be practically feasible.

A better strategy is to rethink the process that leads to the decision of moving a new therapy to Phase III testing to begin with. More research is needed in this regard.””Our study highlights the need to more efficiently identify which new therapies merit Phase III testing,” said lead researcher Changyu Shen, PhD, Associate Professor at Harvard Medical School at the time this study was conducted.

“In order to sustain the rate of innovation in cancer therapeutics and ensure that our patients have access to effective yet affordable therapies, the clinical trial pipeline in oncology must be efficient and accurate. Our work shows that in the past ten years, this has not been the case.”

Most of the trials in this novel study focused on lung, breast, gastrointestinal, and hematologic cancers; trials with fewer than 100 participants were excluded, meaning rare cancer types were less likely to be included. The Phase III trials were predominately two-arm studies of an interventional regimen compared with a control treatment.

“This paper shows that a lot of drugs with ‘positive’ Phase III trials may have a smaller ultimate benefit than was expected, and that changing the threshold for statistical significance is not a quick fix,” said Elizabeth A. Handorf, PhD, Associate Research Professor, Fox Chase Cancer Center, who was not involved in this research. “I think it highlights the need for more efficient study designs, like adaptive trials, and clear definitions of what makes an effect clinically meaningful.”

Journal Reference: Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement. Journal of the National Comprehensive Cancer Network, 2021; 19 (9): 1072 DOI: 10.6004/jnccn.2020.7690

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

FDA Clears Marketing of Genome-Edited Beef Cattle

IISc, India to set up public health centre with Rs105 cr funding from philanthropist

Drs Ella deserve Padma Award for their innovations and management in biotechnology: India’s pioneer recombinant biologist Prof Ramareddy Guntaka

Leave A Reply Cancel Reply

Current Issue – April 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports April 25, 2022
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows April 24, 2022
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic April 24, 2022
  • Guestorial: Demand for Nationalization of Healthcare Services in India April 24, 2022
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea April 15, 2022
  • Phablecare Raises ₹187 Cr In Funding April 11, 2022
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events April 9, 2022
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers April 8, 2022
  • Bose Institute Scientists earn retraction due to manipulation April 5, 2022
  • WHO suspends Covaxin supply to UN agencies April 4, 2022
  • Lockdowns, Not the Pandemic, Created Havoc April 1, 2022
  • WHO selects Biological E to transfer mRNA COVID vaccine tech April 1, 2022
  • Dr. Reddy’s Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany April 1, 2022
  • New Zealand High Court ENDS Vaccine Mandate: “It’s a Gross Violation of Human Rights” April 1, 2022
  • S&T Ministry to support startup in medical implants March 31, 2022
  • FDA Clears Marketing of Genome-Edited Beef Cattle March 30, 2022
  • Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey March 30, 2022
  • Undisclosed industry payments rampant in drug-trial papers in Australia March 29, 2022
  • Fraud Trial of Former Theranos Executive Ramesh’ Sunny’ Balwani Begins March 29, 2022
  • Substandard, fake medical products increased by almost 47% from 2020 to 2021 during pandemic: report March 29, 2022
  • Editorial: Biofuels in India – a perfect waste to wealth and net zero emission energy option March 29, 2022
  • Bharat Biotech and BIOFABRI partner to develop, manufacture and distribute novel TB vaccine March 28, 2022
  • Fibroheal raises debt funding from BIRAC March 28, 2022
  • Editorial – Energy, Renewable Energy and Bioenergy March 28, 2022
  • IISc, India to set up public health centre with Rs105 cr funding from philanthropist March 27, 2022
  • Tamil Nadu makes scientifically dubious claim on vaccines in the Supreme Court March 27, 2022
  • Guest Article: GENE EDITED-CRISPERED FLOWERS: Blooming with grace March 27, 2022
  • Dr. Anthony Fauci, Biden admin operated with missing data as CDC issued pandemic guidance, emails show March 25, 2022
  • Contents – February 2022 March 3, 2022
  • Drs Ella deserve Padma Award for their innovations and management in biotechnology: India’s pioneer recombinant biologist Prof Ramareddy Guntaka February 26, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • Articles- News Reports
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • BioResearch – Industry
  • Biotech – Agriculture
  • Biotech – Healthcare
  • Biotech – Supplies
  • Biotech News – Featured
  • Biotech News – India
  • Biotech News – Industry
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.